Women's Global Impact 2025: Day of Networking, Panels Inspires Attendees
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Some of the most powerful and well-connected women in business gathered at Newsweek's New York headquarters at One World Trade Center today for the company's inaugural Women's Global Impact Forum.
The event kicked off with a breakfast and continued with opening remarks by Newsweek's Editor-in-Chief Jennifer Cunningham who set the stage for the topics of the day, including entrepreneurship, gender equity, women's health, transformations in customer engagement, directing business from the board room, leadership, artificial intelligence, female audiences and how to define having it all.
Across 12 panel discussions and three fireside chats, over 300 guests listened to high-profile guests from Mercedes-Benz, the American Heart Association, SoulCycle, Sakara, Clinique, Hulken and Nissan dispense invaluable advice and tell stories of their success.
One attendee said, "Everything feels really actionable and relatable" when describing the morning's panel lineup.
In addition to the discussions, attendees were able to mingle with one another and learn about each other's respective industries and the impact they were making through their work.
"What I observe in our wellness industry are so many fads, whether it's pursuing cold plunges, protein, Pilates," SoulCycle CEO Evelyn Webster told the crowd. She added that the biggest killer of women in America was heart disease and that exercise was an essential part of staying healthy and well.
"That doesn't mean you need to be running marathons. It means that you need balance, a balanced exercise regimen," she said. "So if that is with SoulCycle, great! But even if it's not SoulCycle, please move your body and get your heart pumping 150 minutes a week."
Webster added that exercise also helped to shape better business leaders. Quoting Legally Blonde icon Elle Woods, she said, "Exercise gives you endorphins, endorphins make you happy. And happy people just make better leaders." The crowd ate it up.
Many attendees showed interest as Kelly Fanning, general manager of Clinique and Dermatological Brands, North America, shared the unusual "reverse mentorship" program offered by her parent company, Estée Lauder.
"Estée Lauder has a long-standing, very formalized program of reverse mentoring," Fanning explained. "Essentially, what it is is more junior-level talent in our organization has the opportunity to be connected with VP-level and above, and they mentor us.
NFL VP Sarah Bishop chats with Women's Global Impact attendees during a networking session on Tuesday, August 5, 2025.
NFL VP Sarah Bishop chats with Women's Global Impact attendees during a networking session on Tuesday, August 5, 2025.
Weston Kloefkorn | For Newsweek
"The first time I did it, I had no idea how to prepare, because I think through our career as a mentor, when you have a mentee, you think about questions you're going to ask," she continued, adding that she'd had a meeting with her reverse mentor on Tuesday morning.
"And from the past year, I've learned TikTok differently. I've gone to a store to shop Sephora with them, see how they shop. What do they do? Why don't they pick our brands? Why do they pick our brands? I've learned AI and how to do the most easy tasks, all the way through to 'Hey, how do I take all this data and just make a report to pull that off my team's plate?' Right?"
During the lunch break, attendees dined on a variety of fare with a New York City theme. After, the panel discussions continued.
Daniella Pierson, founder and CEO of The Newsette and CHASM, discussed how to achieve gender equality in the workplace. "I believe the way that we are actually going to have gender equality... is by making as many badass female entrepreneurs as we can," she said.
KaLeigh Long, founder & CEO of Westwin Elements, urged her fellow female Gen Z aspiring business leaders to focus on "doing something, not being someone."
The day concluded with a one-on-one interview of Indra Nooyi, former chairman and CEO of PepsiCo, by Cunningham, and a cocktail reception.
Glasses at the Women's Global Impact Forum cocktail hour sponsored by Hers at One World Trade Center in New York City.
Glasses at the Women's Global Impact Forum cocktail hour sponsored by Hers at One World Trade Center in New York City.
Weston Kloefkorn | For Newsweek
"Speaking at Newsweek's Women's Global Impact Forum was more than an honor—it was a powerful reminder of what's possible when purpose-driven leadership meets collective ambition. At Nissan, we know that real change begins with listening, learning and leading boldly. Being surrounded by trailblazing women from across industries reaffirmed the strength of our voices and the impact of our actions. Thank you to Newsweek for championing progress and creating space for meaningful dialogue," Allyson Witherspoon, chief marketing officer of Nissan U.S., told Newsweek.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
4 hours ago
- Newsweek
Donald Trump Threatens 250% Tariff on Pharmaceuticals
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump has said that tariffs on pharmaceutical imports could eventually reach up to 250 percent, as his administration works to lower prescription prices for Americans. During an interview with CNBC on Tuesday, the president said he will initially impose a "small tariff on pharmaceuticals," which will rise to 150 percent "in one year, one and a half years maximum," before then eventually jumping to 250 percent. Newsweek reached out to the White House via email for comment. Why It Matters The United States imports a significant amount of pharmaceuticals each year—over $200 billion in 2024, according to the Observatory of Economic Complexity. Should Trump follow through on ramping up these duties, the highest he has threatened on the industry to date, experts believe this could result in significant increases to drug prices in the U.S. However, some health policy experts told Newsweek this could also help rebalance the global drug supply chain to better favor American customers. What To Know Trump said that the tariffs are intended to encourage pharmaceutical companies to move their operations to the U.S.—"because we want pharmaceuticals made in our country"—and to minimize reliance on Europe. He had previously threatened to place 200 percent tariffs on pharmaceuticals in July, but said he would give the industry time before this change came into effect. Trump's threats of pharmaceutical tariffs have raised concerns among experts that these could lead to increased costs and medication shortages in the U.S. In April, the UNC Center for the Business of Health published a report warning that these effects would be especially significant for generic drugs, which are more likely to be imported and operate on lower profit margins than brand-name medications. "A 250 percent tariff on pharmaceuticals would have a significant impact on drug prices," said health economist Jeromie Ballreich. Ballreich told Newsweek that, for branded pharmaceuticals, higher costs from the tariffs will be "passed on to consumers and most likely will be indirect through higher prescription drug insurance premiums." Major pharmaceutical companies across the world saw their shares fall on Wednesday following Trump's announcement. England-based AstraZeneca was down by 1.1 percent, Indiana-based Eli Lilly by 2.3 percent, and Germany-based Bayer AG by nearly 10 percent as of 11:20 ET. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, 2025. President Donald Trump speaks to reporters near Air Force One at Lehigh Valley International Airport on August 3, latest threat comes as the industry braces for the outcome of an ongoing probe by the Commerce Department into the national security implications of America's medicinal imports. The investigation was launched in April by Commerce Secretary Howard Lutnick under Section 232 of the 1962 Trade Expansion Act. Trump did not provide many specifics, such as whether certain classes of pharmaceuticals would be exempt, beyond stating that these tariffs are separate from the country-specific duties that came into effect last week. However, the announcement appears to contradict the terms of the European Union deal struck in July, which the European Commission president said placed a 15-percent tariff "ceiling" on multiple sectors, including pharmaceuticals. Experts had already warned that the 15 percent tariff outlined in the EU trade deal could end up costing the pharmaceutical industry billions. The cost implications could also be seen as conflicting with the administration's separate attempts to lower the price of prescription drugs. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, 2025. President of the European Commission Ursula von der Leyen meets with President Donald Trump in Turnberry, Scotland, on July 27, May, Trump signed an executive order directing the Secretary of Commerce and U.S. Trade Representative to "ensure foreign countries are not engaged in practices that purposefully and unfairly undercut market prices and drive price hikes in the United States." It also proposed that the U.S. be given Most-Favored-Nation (MFN) status, which would require drug companies to offer Americans the same lowest price that drugs are sold for in other countries. Trump followed this up by sending letters to 17 of the world's largest pharmaceutical companies on July 31, outlining steps they must take within 60 days to lower prescription prices for U.S. customers. These include extending MFN pricing to Medicaid, guaranteeing MFN pricing for new medications and negotiating "harder with foreign freeloading nations." The letters also call on the companies to expand direct-to-consumer distribution models to ensure customers "get the same low MFN prices that manufacturers already offer to third-party payers." "At face value, these tariffs are contradictory to his efforts to lower domestic prices," Ballreich told Newsweek. "However, if the tariffs are used as a threat to get drug companies to comply to his administration's [executive orders], including the recent letters to pharmaceutical CEOs, then I think we could see some changes to the pharmaceutical market, which will lower domestic drug prices." Several drugmakers, including Eli Lilly, AstraZeneca and Johnson & Johnson, have also pledged to expand their U.S. manufacturing presence. Prior to the letters being sent, but amid this pressure from the administration, a number had also announced they would be reducing some U.S. drug prices. Health policy analyst Mariana Socal warned that beyond potential cost implications, the tariffs could significantly disrupt the drug development pipeline, potentially jeopardizing the release of new medications. "Aside from the problem of added costs, the uncertainty introduced by tariff policies is detrimental in and of itself to the pharmaceutical market," she told Newsweek, noting that only around one in 10,000 investigated compounds make it to pharmacy shelves, and only do so after decades of work. "Any added uncertainty is likely to be detrimental to this industry, including disincentivizing investors from supporting this industry and pharmaceutical manufacturers from continuing to look for cures," she said. What People Are Saying Health economist Jeromie Ballreich told Newsweek: "This tariff could really disrupt the U.S. prescription drug market, especially the Medicare part D market, where the party plans will be on the hook for the higher price prices and result in significant premium increases to offset these higher prices. Given that, I don't think it's likely that this massive tariff will occur, but rather is a threat to force companies to find solutions based on the executive orders and his recent letters to pharmaceutical CEOs." Mariana Socal, an associate professor at the Johns Hopkins Bloomberg School of Public Health, told Newsweek: "It is critical to continue to identify solutions to lower drug prices in America and improve drug affordability for Americans. However, it is unclear how tariffs would advance affordability. On the opposite, tariffs can be understood as a hidden tax." "In the short term, the likelihood that added costs from tariffs will be passed through to consumers can be reduced by existing contractual agreements with supply chain participants such as distributors and group purchasing organizations, which can protect buyers from price increases for 1-3 years," she added. "However, even if the added cost of tariffs would not necessarily be passed-through to patients in the short term, it could raise costs in the long run." What Happens Next On Sunday, Trump said he would be announcing tariffs on the industry "within the next week or so."
Newsweek
5 hours ago
- Newsweek
Alzheimer's: Scientists Discover What Sparks Disease
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Lithium deficiency in the brain could be a cause of Alzheimer's disease—and a new potential target for treatment. Ten years in the making, this is the finding of researchers at Harvard Medical School who have revealed how lithium plays an essential role in brain function and may provide resistance against brain aging and Alzheimer's. Lithium is a chemical element, currently used as medicine to treat mood disorders like mania and bipolar disorder. "Most people associate lithium with psychiatric treatment. Our study shows, for the first time, that naturally occurring lithium plays a crucial role in maintaining brain health during aging—even at concentrations far below those used in clinical psychiatry," study authors Bruce Yankner and Liviu Aron told Newsweek. The findings are based on a series of experiments in mice and on analyses of human brain tissue and blood samples from individuals in various stages of cognitive health. Lithium carbonate tablet bottles on shelf. Lithium carbonate tablet bottles on shelf. Getty Images "We found that lithium is uniquely depleted in the brains of people with mild cognitive impairment—a precursor to Alzheimer's. This makes lithium deficiency one of the earliest biochemical signs of the disease, possibly years before clinical symptoms appear," the duo explained. "We also saw that higher endogenous lithium levels were associated with preserved cognitive function even in individuals without Alzheimer's. So, this isn't just about preventing disease—it's about supporting healthy brain aging in general. The new revelation helps to explain why some people with Alzheimer's-like abnormalities in the brain don't go on to develop the disease. While genetic and environmental factors play a role, scientists also haven't been able to suggest why some people with the same risk factors might develop it and others don't—until now. The scientists unearthed that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's. In mice, meanwhile, similar lithium depletion accelerated brain pathology (disease or abnormality) and memory decline. They also found reduced lithium levels stemmed from binding to amyloid plaques (misfolded proteins found between nerve cells found in the brains of people with Alzheimer's) and impaired uptake in the brain. One pair of boxes shows fewer green amyloid clusters on the left and more on the right. Another pair of boxes shows a dim arc of purple and red tau on the left and a... One pair of boxes shows fewer green amyloid clusters on the left and more on the right. Another pair of boxes shows a dim arc of purple and red tau on the left and a brighter arc on the right. More Yankner Lab In their final set of experiments, they found a new lithium compound that avoids "capture" by amyloid plaques restored memory in mice. "In people that start experiencing memory loss, the so-called mild cognitive impairment, lithium gets trapped by amyloid plaques—reducing its availability just when it's most needed to protect against inflammation and neurodegeneration," Yankner and Aron explained. "This creates a self-perpetuating feedback loop of worsening pathology and accelerating disease progression and memory loss." This all ties together decades-long observations in patients and provides a new theory of the disease and strategy for early diagnosis, prevention and treatment, according to the researchers. Recently developed treatments that target amyloid beta (a key component of the amyloid plaques) typically don't reverse memory loss and only modestly reduce the rate of decline. "The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach," said Yankner in a statement. Researchers had previously found lithium to be the only metal that had markedly different levels across people with and without Alzheimer's at different stages. But Yankner added in a statement, "Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C. "It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug." Previous population studies have shown that higher lithium levels in the environment, including in drinking water, tracked with lower rates of dementia. Woman hugging her elderly mother. Woman hugging her elderly mother. PIKSEL/Getty Images Yankner's team demonstrated in mice that lithium depletion isn't just linked to Alzheimer's, it actually helps drive it. This raises hope that one day lithium could be used to treat the disease in its entirety rather than focusing on a single factor like amyloid beta or tau (another Alzheimer's-associated protein), Yankner said. Crucially, the researchers discovered that as amyloid beta begins to form deposits in the early stages of dementia in both humans and mouse models, it binds to lithium, reducing lithium's function in the brain. The reduced levels of lithium affect all major brain cell types and, in mice, lead to changes similar to those seen in Alzheimer's disease, including memory loss. Treating mice with the most potent amyloid-evading compound, called lithium orotate, reversed Alzheimer's pathology, prevented brain cell damage and restored memory. While the findings need to be confirmed in humans through clinical trials, they suggest that measuring lithium levels could help screen for early Alzheimer's. They also highlight the importance of testing amyloid-evading lithium compounds for treatment or prevention. While other lithium compounds are already used to treat bipolar disorder and clinical depression, they are given at much higher concentrations that can be toxic to some people, the researchers flag. Yankner's team discovered lithium orotate is effective at one-thousandth that dose— enough to mimic the natural level of lithium in the brain. Mice treated for nearly their entire adult lives showed no evidence of toxicity, the study found. If further studies confirm these findings, the researchers say lithium screening through routine blood tests may one day offer a way to identify individuals at risk for Alzheimer's who would benefit from treatment to prevent or delay disease onset. "Our study adds to growing evidence that Alzheimer's may be preventable—with something as simple as keeping brain lithium at healthy levels as we age," said Yankner and Aron. "Clinical trials [on humans] could test the impact of low-dose supplementation on cognitive health and dementia risk." Before lithium is proved to be safe and effective in protecting against neurodegeneration in humans, Yankner emphasized that people should not take lithium compounds on their own. Do you have a health story to share with Newsweek? Do you have a question about Alzheimer's? Let us know via health@ Reference Aron, L., Ngian, Z. K., Qiu, C., Choi, J., Liang, M., Drake, D. M., Hamplova, S. E., Lacey, E. K., Roche, P., Yuan, M., Hazaveh, S. S., Lee, E. A., Bennett, D. A., & Yankner, B. A. (2025). Lithium deficiency and the onset of Alzheimer's disease. Nature.
Newsweek
5 hours ago
- Newsweek
Son Was Non-Verbal for 8 Years—Now All He Wants To Say Is One Phrase to Mom
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. A 12-year-old boy who was nonverbal for the first eight years of his life has found a new favorite phrase, and it is one his mom can't help but laugh about. Mom-of-three April Perri, from Poughkeepsie, in New York, suspected her son Luca was autistic before he even turned 1. "My intuition was so strong that he was autistic," Perri told Newsweek. "He didn't respond to his name … it was almost like he was deaf. He ran everywhere, had zero fear or safety awareness, and cried all the time." Alongside the challenges came some interesting quirks. "He had incredible skills like reading at 18 months, never played with toys but color-coded them, and had an obsession with numbers, letters and languages," Perri said. "We once went to a wedding when he was a toddler and he climbed all the tables and took the table number cards off and played with them for the rest of the night." As Luca grew up, it became clear to Perri there was another notable difference to the way he behaved: Luca was nonverbal. That is not out of the ordinary for a child with autism spectrum disorder (ASD). A 2021 study in the journal Revista Paulista De Pediatria estimated around 25 to 30 percent of children with ASD fell into the category of nonverbal or minimally verbal. It nevertheless posed a challenge to Perri, who was a single mom at the time. "Luca could read words, but not ask a question, have a two-way conversation or answer a question until he was 5 years old and up," she said. "For example, if he wanted milk, he would just scream 'WHITE!!' until I figured it out." Perri took a proactive approach to her son's situation, though. She got him into a state-funded early intervention program before he was 1. That gave him a head start. Luca received daily home visits from a speech therapist as a toddler and was enrolled in a special-needs preschool where this continued. Now 12, Luca attends public school and is enrolled in the "journeys program," an initiative for kids with autism and other communication issues. In the meantime, Luca's speech has come on leaps and bounds. "Luca really started to be able to have two-way conversations and answer questions around 8 or 9 and has gotten better and better since then," Perri said. Seeing the change this has brought about in her son has been a joy for Luca's mom to witness. "It unlocked a side of him we had never had access to before that," Perri said. "I could ask, 'How was your day at school?' and actually get a sense of how he was feeling and how his day had gone. Before that, I had no idea except for the reports from the teachers." Luca's improved comprehension skills have also allowed him to step out into the world more and more. Perri said she no longer has to worry about meltdowns or safety issues when out in public or at the store. "Just this summer we went on our first vacation with him and it was amazing," Perri said. "It was so great to see him really enjoy himself like any other kid. He has worked so hard for it." Luca is a boy transformed after having found his voice. "He is now the most vocal and outgoing kid in our house and in his class," Perri said. "And, man, is he so funny and charming; his personality shines now!" Although, with his teens fast approaching, Luca has also developed a habit that, while frustrating to his mom, is nevertheless a source of amusement. It is a habit she highlighted in a video posted to Instagram under the handle @thispinklifeilive. As the clip shows, Luca can certainly talk now, but doesn't seem to be that keen on talking to his mom, preferring to respond to her questions with his new favorite phrase: "I don't want to talk right now." Not that Perri is upset at all, preferring, instead, to find the humor in it all. "I just found it ironic that we had worked so hard for so many years to develop his language, only to have him say he didn't want to talk to me," she said. "I loved his ability to self-advocate and respect his boundaries, but, man, was it funny!" Perri started posting videos to social media to "give other families like mine hope." Her message to anyone raising a child with ASD is "take it one day and a time and learn to rest, not quit." "Trust your instinct, start early and try everything," Perri said. "If plan A doesn't work, then there is always plan B to Z to try. Autism is a marathon, not a sprint."
